# Clinofibrate Disrupts the SNORA80B/YTHDC1‐Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC

## TL;DR

A drug called clinofibrate disrupts a specific RNA's role in cholesterol metabolism and drug resistance in esophageal cancer, offering a new treatment strategy.

## Contribution

Identifies SNORA80B as a key driver of cholesterol metabolism in ESCC and repurposes clinofibrate to target this pathway.

## Key findings

- SNORA80B promotes cholesterol metabolism and lipid droplet formation via m6A-YTHDC1 in ESCC.
- Clinofibrate inhibits SNORA80B and synergizes with cisplatin to overcome drug resistance in ESCC.
- SNORA80B forms a feedforward loop with AR signaling through cholesterol metabolic reprogramming.

## Abstract

Esophageal squamous cell carcinoma (ESCC) progression is driven by androgen receptor (AR) signaling, while small nucleolar RNAs (snoRNAs), classically involved in ribosomal RNA processing, are increasingly recognized for non‐classical roles in cancer. However, their function in ESCC remains unknown. This study investigates AR‐regulated snoRNAs and their mechanistic contributions to ESCC pathogenesis. SNORA80B is identified as the most AR‐responsive snoRNA with oncogenic activity by transcriptomic profiling. Beyond its classical role, SNORA80B stabilizes cholesterol metabolism transcripts via N⁶‐methyladenosine (m6A)‐YTHDC1, driving cholesterol/DHT accumulation and lipid droplets (LDs) formation. A feedforward loop is observed wherein DHT‐activated AR upregulates SNORA80B, which further enhances AR signaling through cholesterol metabolic reprogramming. Clinofibrate, identified as a SNORA80B inhibitor through high‐throughput screening of FDA‐approved drugs, disrupts this axis and demonstrates synergistic effects with cisplatin, overcoming resistance in ESCC. The study reveals a novel non‐classical function of SNORA80B in ESCC, establishing it as a key effector of AR‐driven metabolic reprogramming through m⁶A‐dependent regulation. The repurposing of clinofibrate demonstrates the therapeutic potential of targeting snoRNA‐mediated pathways, providing both mechanistic insights and a clinically translatable strategy for ESCC treatment. These findings redefine the functional scope of snoRNAs in cancer pathogenesis.

This study uncovers a non‐canonical role of SNORA80B in ESCC, showing it mediates AR‐driven metabolic reprogramming via N⁶‐methyladenosine (m6A) methylation. By binding YTHDC1, SNORA80B stabilizes cholesterol‐metabolic enzyme mRNAs and promotes tumor progression. The FDA‐approved drug clinofibrate inhibits SNORA80B by disrupting cholesterol homeostasis, synergistically resensitizing cisplatin‐resistant ESCC to therapy.